Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| HENRY SCHEIN INCHSIC · Entity 3536 | Director | March 06, 2026 | March 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
HENRY SCHEIN INC
Report date March 06, 2026 · Filed March 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.01 per shareSEC Table I · non-derivative | Direct | 12,520 |
Reported balance
After 2026-03-06 transaction · row 1
1 source rowRow 1 · 2026-03-06 · Grant · Acquired 2,577 · Balance 12,520 F1: Acquired pursuant to the Issuer's 2023 Non-Employee Director Stock Incentive Plan. Subject to certain exceptions, such restricted stock units will vest subject to (i) the passage of a specified period of time (12-months cliff vesting) and (ii) the reporting person's continued performance of services for the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Acquired pursuant to the Issuer's 2023 Non-Employee Director Stock Incentive Plan. Subject to certain exceptions, such restricted stock units will vest subject to (i) the passage of a specified period of time (12-months cliff vesting) and (ii) the reporting person's continued performance of services for the Issuer.
Past disclosures · reporting ended (4)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Adverum Biotechnologies, Inc.
Report date December 09, 2025 · Filed December 10, 2025
Section 16 reporting ended · disclosed 2025-12-10. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $128.50 | Direct | 0 |
Reported balance
After 2025-12-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-12-09 · Disposition to issuer · Disposed 4,500 · Balance 0 F1: In connection with the terms of an Agreement and Plan of Merger, dated as of October 24, 2025 (the "Merger Agreement"), by and among the Issuer, Eli Lilly and Company ("Parent") and Parent's direct wholly owned subsidiary, Flying Tigers Acquisition Corporation ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's Common Stock. In exchange for each share, tendering stockholders received: (i) $3.56 per share in cash, without interest and less any applicable tax withholding (the "Cash Consideration"); plus (ii) one non-tradable contingent value right (each, a "CVR"), which represents the contractual right to receive up to two contingent cash payments of up to an aggregate of $8.91 per CVR, net to the stockholder in cash, F2: (continued from footnote 1) without interest and less any applicable tax withholding, upon the achievement of both specified milestones in accordance with the terms and subject to the conditions of a contingent value rights agreement (the "CVR Agreement") with Computershare Inc. and its affiliate, Computershare Trust Company, N.A, as the rights agent. After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer (the "Merger"), effective as of December 9, 2025, with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent (the "Effective Time"). F3: Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an "Out-of-the-Money Option"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.90 | Direct | 0 |
Reported balance
After 2025-12-09 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-12-09 · Disposition to issuer · Disposed 4,000 · Balance 0 F1: In connection with the terms of an Agreement and Plan of Merger, dated as of October 24, 2025 (the "Merger Agreement"), by and among the Issuer, Eli Lilly and Company ("Parent") and Parent's direct wholly owned subsidiary, Flying Tigers Acquisition Corporation ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's Common Stock. In exchange for each share, tendering stockholders received: (i) $3.56 per share in cash, without interest and less any applicable tax withholding (the "Cash Consideration"); plus (ii) one non-tradable contingent value right (each, a "CVR"), which represents the contractual right to receive up to two contingent cash payments of up to an aggregate of $8.91 per CVR, net to the stockholder in cash, F2: (continued from footnote 1) without interest and less any applicable tax withholding, upon the achievement of both specified milestones in accordance with the terms and subject to the conditions of a contingent value rights agreement (the "CVR Agreement") with Computershare Inc. and its affiliate, Computershare Trust Company, N.A, as the rights agent. After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer (the "Merger"), effective as of December 9, 2025, with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent (the "Effective Time"). F3: Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an "Out-of-the-Money Option"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.60 | Direct | 0 |
Reported balance
After 2025-12-09 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-12-09 · Disposition to issuer · Disposed 4,000 · Balance 0 F1: In connection with the terms of an Agreement and Plan of Merger, dated as of October 24, 2025 (the "Merger Agreement"), by and among the Issuer, Eli Lilly and Company ("Parent") and Parent's direct wholly owned subsidiary, Flying Tigers Acquisition Corporation ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's Common Stock. In exchange for each share, tendering stockholders received: (i) $3.56 per share in cash, without interest and less any applicable tax withholding (the "Cash Consideration"); plus (ii) one non-tradable contingent value right (each, a "CVR"), which represents the contractual right to receive up to two contingent cash payments of up to an aggregate of $8.91 per CVR, net to the stockholder in cash, F2: (continued from footnote 1) without interest and less any applicable tax withholding, upon the achievement of both specified milestones in accordance with the terms and subject to the conditions of a contingent value rights agreement (the "CVR Agreement") with Computershare Inc. and its affiliate, Computershare Trust Company, N.A, as the rights agent. After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer (the "Merger"), effective as of December 9, 2025, with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent (the "Effective Time"). F3: Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an "Out-of-the-Money Option"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.32 | Direct | 0 |
Reported balance
After 2025-12-09 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-12-09 · Disposition to issuer · Disposed 10,520 · Balance 0 F1: In connection with the terms of an Agreement and Plan of Merger, dated as of October 24, 2025 (the "Merger Agreement"), by and among the Issuer, Eli Lilly and Company ("Parent") and Parent's direct wholly owned subsidiary, Flying Tigers Acquisition Corporation ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's Common Stock. In exchange for each share, tendering stockholders received: (i) $3.56 per share in cash, without interest and less any applicable tax withholding (the "Cash Consideration"); plus (ii) one non-tradable contingent value right (each, a "CVR"), which represents the contractual right to receive up to two contingent cash payments of up to an aggregate of $8.91 per CVR, net to the stockholder in cash, F2: (continued from footnote 1) without interest and less any applicable tax withholding, upon the achievement of both specified milestones in accordance with the terms and subject to the conditions of a contingent value rights agreement (the "CVR Agreement") with Computershare Inc. and its affiliate, Computershare Trust Company, N.A, as the rights agent. After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer (the "Merger"), effective as of December 9, 2025, with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent (the "Effective Time"). F3: Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an "Out-of-the-Money Option"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.32 | Direct | 0 |
Reported balance
After 2025-12-09 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2025-12-09 · Disposition to issuer · Disposed 10,450 · Balance 0 F1: In connection with the terms of an Agreement and Plan of Merger, dated as of October 24, 2025 (the "Merger Agreement"), by and among the Issuer, Eli Lilly and Company ("Parent") and Parent's direct wholly owned subsidiary, Flying Tigers Acquisition Corporation ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's Common Stock. In exchange for each share, tendering stockholders received: (i) $3.56 per share in cash, without interest and less any applicable tax withholding (the "Cash Consideration"); plus (ii) one non-tradable contingent value right (each, a "CVR"), which represents the contractual right to receive up to two contingent cash payments of up to an aggregate of $8.91 per CVR, net to the stockholder in cash, F2: (continued from footnote 1) without interest and less any applicable tax withholding, upon the achievement of both specified milestones in accordance with the terms and subject to the conditions of a contingent value rights agreement (the "CVR Agreement") with Computershare Inc. and its affiliate, Computershare Trust Company, N.A, as the rights agent. After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer (the "Merger"), effective as of December 9, 2025, with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent (the "Effective Time"). F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding stock option granted under a Company Equity Plan having an exercise price less than the Cash Consideration (each such option, a "Cash-Out Stock Option") that was outstanding immediately prior to the Effective Time, whether or not vested, was automatically cancelled, and in exchange for such cancellation, the holder of such Cash-Out Stock Option received (i) an amount in cash, without interest and less any applicable tax withholdings, equal to the product of (a) the excess, if any, of the Cash Consideration over the applicable exercise price per share underlying such Cash-Out Stock Option multiplied by (b) the total number of shares subject to such Cash-Out Stock Option and (ii) one CVR for each share subject to such Cash-Out Stock Option (without regard to vesting). |
Filing footnotes · ownership attribution and instrument terms
F1: In connection with the terms of an Agreement and Plan of Merger, dated as of October 24, 2025 (the "Merger Agreement"), by and among the Issuer, Eli Lilly and Company ("Parent") and Parent's direct wholly owned subsidiary, Flying Tigers Acquisition Corporation ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's Common Stock. In exchange for each share, tendering stockholders received: (i) $3.56 per share in cash, without interest and less any applicable tax withholding (the "Cash Consideration"); plus (ii) one non-tradable contingent value right (each, a "CVR"), which represents the contractual right to receive up to two contingent cash payments of up to an aggregate of $8.91 per CVR, net to the stockholder in cash,
F2: (continued from footnote 1) without interest and less any applicable tax withholding, upon the achievement of both specified milestones in accordance with the terms and subject to the conditions of a contingent value rights agreement (the "CVR Agreement") with Computershare Inc. and its affiliate, Computershare Trust Company, N.A, as the rights agent. After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer (the "Merger"), effective as of December 9, 2025, with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent (the "Effective Time").
F3: Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an "Out-of-the-Money Option"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time.
F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding stock option granted under a Company Equity Plan having an exercise price less than the Cash Consideration (each such option, a "Cash-Out Stock Option") that was outstanding immediately prior to the Effective Time, whether or not vested, was automatically cancelled, and in exchange for such cancellation, the holder of such Cash-Out Stock Option received (i) an amount in cash, without interest and less any applicable tax withholdings, equal to the product of (a) the excess, if any, of the Cash Consideration over the applicable exercise price per share underlying such Cash-Out Stock Option multiplied by (b) the total number of shares subject to such Cash-Out Stock Option and (ii) one CVR for each share subject to such Cash-Out Stock Option (without regard to vesting).
CTI BIOPHARMA CORP
Report date June 26, 2023 · Filed June 26, 2023
Section 16 reporting ended · disclosed 2023-06-26. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-06-26 transaction · row 1
1 source rowRow 1 · 2023-06-26 · Other · Disposed 48,639 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 10, 2023, by and among the Issuer, Swedish Orphan Biovitrum AB (publ) ("Parent"), and Cleopatra Acquisition Corp., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer, effective as of June 26, 2023 (the "Effective Time"). At the Effective Time, each issued and outstanding share of Company Common Stock was cancelled and converted into the right to receive $9.10 in cash (the "Offer Price") without interest and subject to applicable withholding taxes. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.25 | Direct | 0 |
Reported balance
After 2023-06-26 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-06-26 · Disposition to issuer · Disposed 50,000 · Balance 0 F2: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.61 | Direct | 0 |
Reported balance
After 2023-06-26 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-06-26 · Disposition to issuer · Disposed 60,000 · Balance 0 F2: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.84 | Direct | 0 |
Reported balance
After 2023-06-26 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-06-26 · Disposition to issuer · Disposed 120,000 · Balance 0 F2: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.00 | Direct | 0 |
Reported balance
After 2023-06-26 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-06-26 · Disposition to issuer · Disposed 126,000 · Balance 0 F2: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.30 | Direct | 0 |
Reported balance
After 2023-06-26 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2023-06-26 · Disposition to issuer · Disposed 80,000 · Balance 0 F2: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.49 | Direct | 0 |
Reported balance
After 2023-06-26 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2023-06-26 · Disposition to issuer · Disposed 80,000 · Balance 0 F2: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.08 | Direct | 0 |
Reported balance
After 2023-06-26 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2023-06-26 · Disposition to issuer · Disposed 80,000 · Balance 0 F2: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 10, 2023, by and among the Issuer, Swedish Orphan Biovitrum AB (publ) ("Parent"), and Cleopatra Acquisition Corp., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer, effective as of June 26, 2023 (the "Effective Time"). At the Effective Time, each issued and outstanding share of Company Common Stock was cancelled and converted into the right to receive $9.10 in cash (the "Offer Price") without interest and subject to applicable withholding taxes.
F2: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option.
LEGACY LIFEPOINT HEALTH, INC.
Report date November 16, 2018 · Filed November 20, 2018
Section 16 reporting ended · disclosed 2018-11-20. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| CommonSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-11-16 transaction · row 1
1 source rowRow 1 · 2018-11-16 · Disposition to issuer · Disposed 8,311 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger between the Issuer, RegionalCare Hospital Partners Holdings, Inc. d/b/a RCCH HealthCare Partners, and Legend Merger Sub, Inc. (the "Merger Agreement"), each share of Common Stock issued and outstanding immediately prior to the effective time of the merger was canceled and converted into the right to receive $65.00 in cash, without interest. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2021-06-06 | Direct | 0 |
Reported balance
After 2018-11-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-11-16 · Disposition to issuer · Disposed 3,379 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, each outstanding restricted stock unit, whether vested or unvested, became fully vested as of the effective time of the merger, and was canceled and converted into the right to receive an amount in cash, without interest and less any applicable withholding taxes, equal to the merger consideration of $65.00 per share multiplied by the number of shares of common stock subject to such restricted stock unit award. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2020-06-08 | Direct | 0 |
Reported balance
After 2018-11-16 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-11-16 · Disposition to issuer · Disposed 3,008 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, each outstanding restricted stock unit, whether vested or unvested, became fully vested as of the effective time of the merger, and was canceled and converted into the right to receive an amount in cash, without interest and less any applicable withholding taxes, equal to the merger consideration of $65.00 per share multiplied by the number of shares of common stock subject to such restricted stock unit award. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2019-06-08 | Direct | 0 |
Reported balance
After 2018-11-16 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2018-11-16 · Disposition to issuer · Disposed 2,684 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, each outstanding restricted stock unit, whether vested or unvested, became fully vested as of the effective time of the merger, and was canceled and converted into the right to receive an amount in cash, without interest and less any applicable withholding taxes, equal to the merger consideration of $65.00 per share multiplied by the number of shares of common stock subject to such restricted stock unit award. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the terms of the Agreement and Plan of Merger between the Issuer, RegionalCare Hospital Partners Holdings, Inc. d/b/a RCCH HealthCare Partners, and Legend Merger Sub, Inc. (the "Merger Agreement"), each share of Common Stock issued and outstanding immediately prior to the effective time of the merger was canceled and converted into the right to receive $65.00 in cash, without interest.
F2: Pursuant to the terms of the Merger Agreement, each outstanding restricted stock unit, whether vested or unvested, became fully vested as of the effective time of the merger, and was canceled and converted into the right to receive an amount in cash, without interest and less any applicable withholding taxes, equal to the merger consideration of $65.00 per share multiplied by the number of shares of common stock subject to such restricted stock unit award.
UNITEDHEALTH GROUP INC
Report date June 05, 2012 · Filed June 07, 2012
Section 16 reporting ended · disclosed 2012-06-07. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 116,885.97 |
Reported balance
After 2012-06-05 transaction · row 1
1 source rowRow 1 · 2012-06-05 · Tax withholding · Disposed 3,243 · Balance 116,885.97 |
| Common StockSEC Table I · non-derivative | Indirectby 401(k) | 58.0278 |
Reported balance
Holding disclosure · report date 2012-06-05 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 58.0278 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 05, 2012 Filed Jun 7, 2012 21:30 UTC | UNITEDHEALTH GROUP INC UNH · Entity 2809 | Tax withholdingCommon Stock | 3,243 | $56.04 | $181,737.72 |
DisclosureSEC source: 0001209191-12-032850 · doc4.xml · nonDerivative · entry 1 Tuckson Reed Vaughn · CIK 0001511051 · EVP & Chief of Medical Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,885.97 Read SEC document |
| March 19, 2012 Filed Mar 20, 2012 21:42 UTC | UNITEDHEALTH GROUP INC UNH · Entity 2809 | GrantCommon Stock | 102.104 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-12-019223 · doc4.xml · nonDerivative · entry 1 Tuckson Reed Vaughn · CIK 0001511051 · EVP & Chief of Medical Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,128.97 F1 · shares: Represents payment of dividend equivalents on outstanding restricted stock units. The dividend equivalents are subject to the same terms as the underlying restricted stock units and are forfeited if the related award does not vest. Read SEC document |
| February 09, 2012 Filed Feb 10, 2012 21:34 UTC | UNITEDHEALTH GROUP INC UNH · Entity 2809 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 110,000 | $0.00 Strike: $42.87 | $0.00 |
DisclosureSEC source: 0001209191-12-009064 · doc4.xml · derivative · entry 12 Tuckson Reed Vaughn · CIK 0001511051 · EVP & Chief of Medical Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 110,000 shares Expires 2014-11-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock options vested at a rate of 50% annually on November 4 from the years 2007 through 2008. Read SEC document |
| February 09, 2012 Filed Feb 10, 2012 21:34 UTC | UNITEDHEALTH GROUP INC UNH · Entity 2809 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 110,000 | $0.00 Strike: $43.68 | $0.00 |
DisclosureSEC source: 0001209191-12-009064 · doc4.xml · derivative · entry 11 Tuckson Reed Vaughn · CIK 0001511051 · EVP & Chief of Medical Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 110,000 shares Expires 2014-11-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock options vested at a rate of 50% annually on November 4 from the years 2005 through 2006. Read SEC document |
| February 09, 2012 Filed Feb 10, 2012 21:34 UTC | UNITEDHEALTH GROUP INC UNH · Entity 2809 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 17,500 | $0.00 Strike: $28.10 | $0.00 |
DisclosureSEC source: 0001209191-12-009064 · doc4.xml · derivative · entry 10 Tuckson Reed Vaughn · CIK 0001511051 · EVP & Chief of Medical Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,500 shares Expires 2013-10-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 09, 2012 Filed Feb 10, 2012 21:34 UTC | UNITEDHEALTH GROUP INC UNH · Entity 2809 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 52,500 | $0.00 Strike: $30.98 | $0.00 |
DisclosureSEC source: 0001209191-12-009064 · doc4.xml · derivative · entry 9 Tuckson Reed Vaughn · CIK 0001511051 · EVP & Chief of Medical Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 52,500 shares Expires 2013-10-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock options vested at a rate of 33% annually on October 28 from the years 2004 through 2006. Read SEC document |
| February 09, 2012 Filed Feb 10, 2012 21:34 UTC | UNITEDHEALTH GROUP INC UNH · Entity 2809 | SaleCommon Stock | 290,000 | $53.12 | $15,405,206.00 |
DisclosureSEC source: 0001209191-12-009064 · doc4.xml · nonDerivative · entry 7 Tuckson Reed Vaughn · CIK 0001511051 · EVP & Chief of Medical Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,026.866 F1 · price: This transaction was executed in multiple trades ranging from $53.09 to $53.145 per share. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| February 09, 2012 Filed Feb 10, 2012 21:34 UTC | UNITEDHEALTH GROUP INC UNH · Entity 2809 | Exercise / conversionCommon Stock | 110,000 | $42.87 | $4,715,150.00 |
DisclosureSEC source: 0001209191-12-009064 · doc4.xml · nonDerivative · entry 6 Tuckson Reed Vaughn · CIK 0001511051 · EVP & Chief of Medical Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 410,026.866 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 09, 2012 Filed Feb 10, 2012 21:34 UTC | UNITEDHEALTH GROUP INC UNH · Entity 2809 | Exercise / conversionCommon Stock | 110,000 | $43.68 | $4,804,690.00 |
DisclosureSEC source: 0001209191-12-009064 · doc4.xml · nonDerivative · entry 5 Tuckson Reed Vaughn · CIK 0001511051 · EVP & Chief of Medical Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,026.866 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 09, 2012 Filed Feb 10, 2012 21:34 UTC | UNITEDHEALTH GROUP INC UNH · Entity 2809 | Exercise / conversionCommon Stock | 17,500 | $28.10 | $491,750.00 |
DisclosureSEC source: 0001209191-12-009064 · doc4.xml · nonDerivative · entry 4 Tuckson Reed Vaughn · CIK 0001511051 · EVP & Chief of Medical Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 190,026.866 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 09, 2012 Filed Feb 10, 2012 21:34 UTC | UNITEDHEALTH GROUP INC UNH · Entity 2809 | Exercise / conversionCommon Stock | 52,500 | $30.98 | $1,626,397.50 |
DisclosureSEC source: 0001209191-12-009064 · doc4.xml · nonDerivative · entry 3 Tuckson Reed Vaughn · CIK 0001511051 · EVP & Chief of Medical Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,526.866 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 09, 2012 Filed Feb 10, 2012 21:34 UTC | UNITEDHEALTH GROUP INC UNH · Entity 2809 | Tax withholdingCommon Stock | 2,914 | $53.06 | $154,616.84 |
DisclosureSEC source: 0001209191-12-009064 · doc4.xml · nonDerivative · entry 2 Tuckson Reed Vaughn · CIK 0001511051 · EVP & Chief of Medical Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,026.866 Read SEC document |
| February 09, 2012 Filed Feb 10, 2012 21:34 UTC | UNITEDHEALTH GROUP INC UNH · Entity 2809 | Tax withholdingCommon Stock | 2,322 | $53.06 | $123,205.32 |
DisclosureSEC source: 0001209191-12-009064 · doc4.xml · nonDerivative · entry 1 Tuckson Reed Vaughn · CIK 0001511051 · EVP & Chief of Medical Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,940.866 Read SEC document |
| February 07, 2012 Filed Feb 9, 2012 21:42 UTC | UNITEDHEALTH GROUP INC UNH · Entity 2809 | GrantCommon Stock | 19,220 | $52.03 | $1,000,016.60 |
DisclosureSEC source: 0001209191-12-008721 · doc4.xml · nonDerivative · entry 1 Tuckson Reed Vaughn · CIK 0001511051 · EVP & Chief of Medical Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,262.866 F1 · shares: The restricted stock units will vest at a rate of 33% on December 28, 2012; February 7, 2014; and February 7, 2015. F2 · balance_after: Amount does not include performance-based restricted stock units granted to the executive officer on February 7, 2012, as performance awards not tied to stock price are not derivative securities for purposes of Section 16 under guidance from the staff of the SEC. The number of performance-based restricted stock units that the executive officer will receive will be determined at the end of the 3-year performance period and will be dependent upon the achievement of cumulative 3-year EPS and average return-on-equity performance metrics approved by the Compensation and Human Resources Committee. The target number of performance-based restricted stock units is 19,220. Read SEC document |
| February 03, 2012 Filed Feb 7, 2012 21:50 UTC | UNITEDHEALTH GROUP INC UNH · Entity 2809 | Tax withholdingCommon Stock | 3,005 | $51.31 | $154,186.55 |
DisclosureSEC source: 0001209191-12-008175 · doc4.xml · nonDerivative · entry 1 Tuckson Reed Vaughn · CIK 0001511051 · EVP & Chief of Medical Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,042.866 F1 · balance_after: Includes shares received through UnitedHealth Group Incorporated's Employee Stock Purchase Plan. Read SEC document |
| December 21, 2011 Filed Dec 22, 2011 23:38 UTC | UNITEDHEALTH GROUP INC UNH · Entity 2809 | Tax withholdingCommon Stock | 594 | $49.99 | $29,694.06 |
DisclosureSEC source: 0001209191-11-062896 · doc4.xml · nonDerivative · entry 2 Tuckson Reed Vaughn · CIK 0001511051 · EVP & Chief of Medical Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,930.382 F3 · shares: Represents the cancellation of shares for the payment of a FICA tax liability. F2 · balance_after: Includes shares received through UnitedHealth Group Incorporated's Employee Stock Purchase Plan. Read SEC document |
| December 21, 2011 Filed Dec 22, 2011 23:38 UTC | UNITEDHEALTH GROUP INC UNH · Entity 2809 | GrantCommon Stock | 77.996 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-11-062896 · doc4.xml · nonDerivative · entry 1 Tuckson Reed Vaughn · CIK 0001511051 · EVP & Chief of Medical Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,524.382 F1 · shares: Represents payment of dividend equivalents on outstanding restricted stock units. The dividend equivalents are subject to the same terms as the underlying restricted stock units and are forfeited if the related award does not vest. F2 · balance_after: Includes shares received through UnitedHealth Group Incorporated's Employee Stock Purchase Plan. Read SEC document |
| September 21, 2011 Filed Sep 22, 2011 22:30 UTC | UNITEDHEALTH GROUP INC UNH · Entity 2809 | GrantCommon Stock | 80.938 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-11-048798 · doc4.xml · nonDerivative · entry 2 Tuckson Reed Vaughn · CIK 0001511051 · EVP & Chief of Medical Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,926.915 F1 · shares: Represents payment of dividend equivalents on outstanding restricted stock units. The dividend equivalents are subject to the same terms as the underlying restricted stock units and are forfeited if the related award does not vest. Read SEC document |
| June 21, 2011 Filed Sep 22, 2011 22:30 UTC | UNITEDHEALTH GROUP INC UNH · Entity 2809 | GrantCommon Stock | 74.182 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-11-048798 · doc4.xml · nonDerivative · entry 1 Tuckson Reed Vaughn · CIK 0001511051 · EVP & Chief of Medical Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,845.977 F1 · shares: Represents payment of dividend equivalents on outstanding restricted stock units. The dividend equivalents are subject to the same terms as the underlying restricted stock units and are forfeited if the related award does not vest. Read SEC document |
| June 05, 2011 Filed Jun 7, 2011 21:34 UTC | UNITEDHEALTH GROUP INC UNH · Entity 2809 | Tax withholdingCommon Stock | 3,243 | $48.85 | $158,420.55 |
DisclosureSEC source: 0001209191-11-033556 · doc4.xml · nonDerivative · entry 1 Tuckson Reed Vaughn · CIK 0001511051 · EVP & Chief of Medical Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,771.795 Read SEC document |
| May 20, 2011 Filed May 24, 2011 20:23 UTC | UNITEDHEALTH GROUP INC UNH · Entity 2809 | Exercise / conversionNon-qualified stock option (right to buy) · Derivative | 140,000 | $0.00 Strike: $24.86 | $0.00 |
DisclosureSEC source: 0001209191-11-030690 · doc4.xml · derivative · entry 4 Tuckson Reed Vaughn · CIK 0001511051 · EVP & Chief of Medical Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 140,000 shares Expires 2013-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 20, 2011 Filed May 24, 2011 20:23 UTC | UNITEDHEALTH GROUP INC UNH · Entity 2809 | SaleCommon stock | 140,000 | $50.35 | $7,048,692.00 |
DisclosureSEC source: 0001209191-11-030690 · doc4.xml · nonDerivative · entry 2 Tuckson Reed Vaughn · CIK 0001511051 · EVP & Chief of Medical Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,014.795 F1 · price: This transaction was executed in multiple trades ranging from $50.26 to $50.44 per share. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| May 20, 2011 Filed May 24, 2011 20:23 UTC | UNITEDHEALTH GROUP INC UNH · Entity 2809 | Exercise / conversionCommon stock | 140,000 | $24.86 | $3,480,932.00 |
DisclosureSEC source: 0001209191-11-030690 · doc4.xml · nonDerivative · entry 1 Tuckson Reed Vaughn · CIK 0001511051 · EVP & Chief of Medical Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 252,014.795 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 21, 2011 Filed Mar 22, 2011 22:35 UTC | UNITEDHEALTH GROUP INC UNH · Entity 2809 | GrantCommon Stock | 68.795 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-11-019269 · doc4.xml · nonDerivative · entry 1 Tuckson Reed Vaughn · CIK 0001511051 · EVP & Chief of Medical Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,014.795 F1 · shares: Represents payment of dividend equivalents on outstanding restricted stock units. The dividend equivalents are subject to the same terms as the underlying restricted stock units and are forfeited if the related award does not vest. Read SEC document |
| February 09, 2011 Filed Feb 11, 2011 21:30 UTC | UNITEDHEALTH GROUP INC UNH · Entity 2809 | GrantCommon Stock | 23,770 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-11-008871 · doc4.xml · nonDerivative · entry 2 Tuckson Reed Vaughn · CIK 0001511051 · EVP & Chief of Medical Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,946 F1 · shares: The restricted stock units will vest at a rate of 33% on February 9, 2012; December 28, 2012; and February 9, 2014. F2 · balance_after: Amount does not include performance-based restricted stock units granted to the executive officer on February 9, 2011, as performance awards not tied to stock price are not derivative securities for purposes of Section 16 under guidance from the staff of the SEC. The number of performance-based restricted stock units that the executive officer will receive will be determined at the end of the 3-year performance period and will be dependent upon the achievement of cumulative 3-year EPS and average return-on-equity performance metrics approved by the Compensation and Human Resources Committee. The target number of performance-based restricted stock units is 23,770. Read SEC document |
| February 09, 2011 Filed Feb 11, 2011 21:30 UTC | UNITEDHEALTH GROUP INC UNH · Entity 2809 | Tax withholdingCommon Stock | 2,134 | $42.07 | $89,777.38 |
DisclosureSEC source: 0001209191-11-008871 · doc4.xml · nonDerivative · entry 1 Tuckson Reed Vaughn · CIK 0001511051 · EVP & Chief of Medical Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,176 Read SEC document |
| February 03, 2011 Filed Feb 4, 2011 23:55 UTC | UNITEDHEALTH GROUP INC UNH · Entity 2809 | Tax withholdingCommon Stock | 2,783 | $43.04 | $119,780.32 |
DisclosureSEC source: 0001209191-11-007323 · doc4.xml · nonDerivative · entry 1 Tuckson Reed Vaughn · CIK 0001511051 · EVP & Chief of Medical Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,310 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.